A recent pan-cancer next-generation sequencing profiling demonstrated that ~7% of cancers harbor gain-of-function FGFR aberrations, with varying frequencies between family members (FGFR1 > FGFR3 > FGFR2 > FGFR4) [39]. This evidence concerns the gene FGFR2 and cancer.